IBDEI15V ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20768,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,20769,0)
 ;;=282.46^^118^1253^53
 ;;^UTILITY(U,$J,358.3,20769,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20769,1,1,0)
 ;;=1^282.46
 ;;^UTILITY(U,$J,358.3,20769,1,8,0)
 ;;=8^Thalassemia Minor
 ;;^UTILITY(U,$J,358.3,20769,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,20770,0)
 ;;=282.47^^118^1253^19
 ;;^UTILITY(U,$J,358.3,20770,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20770,1,1,0)
 ;;=1^282.47
 ;;^UTILITY(U,$J,358.3,20770,1,8,0)
 ;;=8^Hemoglobin E-beta Thalassemia
 ;;^UTILITY(U,$J,358.3,20770,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,20771,0)
 ;;=282.49^^118^1253^42
 ;;^UTILITY(U,$J,358.3,20771,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20771,1,1,0)
 ;;=1^282.49
 ;;^UTILITY(U,$J,358.3,20771,1,8,0)
 ;;=8^Oth Thalassemia
 ;;^UTILITY(U,$J,358.3,20771,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,20772,0)
 ;;=282.5^^118^1253^49
 ;;^UTILITY(U,$J,358.3,20772,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20772,1,1,0)
 ;;=1^282.5
 ;;^UTILITY(U,$J,358.3,20772,1,8,0)
 ;;=8^Sickle-cell Trait
 ;;^UTILITY(U,$J,358.3,20772,2)
 ;;=^110419
 ;;^UTILITY(U,$J,358.3,20773,0)
 ;;=282.60^^118^1253^47
 ;;^UTILITY(U,$J,358.3,20773,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20773,1,1,0)
 ;;=1^282.60
 ;;^UTILITY(U,$J,358.3,20773,1,8,0)
 ;;=8^Sickle-cell Disease Unspec
 ;;^UTILITY(U,$J,358.3,20773,2)
 ;;=^330077
 ;;^UTILITY(U,$J,358.3,20774,0)
 ;;=282.62^^118^1253^17
 ;;^UTILITY(U,$J,358.3,20774,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20774,1,1,0)
 ;;=1^282.62
 ;;^UTILITY(U,$J,358.3,20774,1,8,0)
 ;;=8^Hb-SS Disease w/ Crisis
 ;;^UTILITY(U,$J,358.3,20774,2)
 ;;=^330079
 ;;^UTILITY(U,$J,358.3,20775,0)
 ;;=282.61^^118^1253^18
 ;;^UTILITY(U,$J,358.3,20775,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20775,1,1,0)
 ;;=1^282.61
 ;;^UTILITY(U,$J,358.3,20775,1,8,0)
 ;;=8^Hb-SS Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,20775,2)
 ;;=^330078
 ;;^UTILITY(U,$J,358.3,20776,0)
 ;;=282.63^^118^1253^51
 ;;^UTILITY(U,$J,358.3,20776,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20776,1,1,0)
 ;;=1^282.63
 ;;^UTILITY(U,$J,358.3,20776,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,20776,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,20777,0)
 ;;=282.64^^118^1253^50
 ;;^UTILITY(U,$J,358.3,20777,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20777,1,1,0)
 ;;=1^282.64
 ;;^UTILITY(U,$J,358.3,20777,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,20777,2)
 ;;=^329911
 ;;^UTILITY(U,$J,358.3,20778,0)
 ;;=282.68^^118^1253^38
 ;;^UTILITY(U,$J,358.3,20778,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20778,1,1,0)
 ;;=1^282.68
 ;;^UTILITY(U,$J,358.3,20778,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,20778,2)
 ;;=^329912
 ;;^UTILITY(U,$J,358.3,20779,0)
 ;;=282.69^^118^1253^37
 ;;^UTILITY(U,$J,358.3,20779,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20779,1,1,0)
 ;;=1^282.69
 ;;^UTILITY(U,$J,358.3,20779,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,20779,2)
 ;;=^330081
 ;;^UTILITY(U,$J,358.3,20780,0)
 ;;=282.7^^118^1253^34
 ;;^UTILITY(U,$J,358.3,20780,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20780,1,1,0)
 ;;=1^282.7
 ;;^UTILITY(U,$J,358.3,20780,1,8,0)
 ;;=8^Oth Hemoglobinopathies
 ;;^UTILITY(U,$J,358.3,20780,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,20781,0)
 ;;=282.8^^118^1253^40
 ;;^UTILITY(U,$J,358.3,20781,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20781,1,1,0)
 ;;=1^282.8
 ;;^UTILITY(U,$J,358.3,20781,1,8,0)
 ;;=8^Oth Spec Hereditary Hemolytic
 ;;^UTILITY(U,$J,358.3,20781,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,20782,0)
 ;;=283.10^^118^1253^31
